Teva Pharmaceutical Industries Ltd DEFA14A, filed Apr 13, 2022

Teva Pharmaceutical

Industries Limited

Online

Go to www.investorvote.com/teva or scan the QR code – login details are located in the shaded bar below.

Votes submitted electronically must be received by 8 a.m., Eastern Time, on June 21, 2022.

Teva Pharmaceutical Industries Ltd (TEVA)

DEFA14A 2022-04-13

View Original

Added on October 18, 2026

Search and read filings like this one from Claude or ChatGPT with the SEC filings MCP server →


☐		Preliminary Proxy Statement

☐		Confidential, For Use of the Commission Only (as permitted by Rule 14a-6(e)(2))

☐		Definitive Proxy Statement

☒		Definitive Additional Materials

☐		Soliciting Material under §240.14a-12



☒	No fee required.

☐	Fee computed on table below per Exchange Act Rules 14a-6(i) (1) and 0-11.

	(1)	Title of each class of securities to which transaction applies:
	(2)	Aggregate number of securities to which transaction applies:
	(3)	Per unit price or other underlying value of transaction computed pursuant to Exchange Act Rule 0-11 (set forth the amount on which the filing fee is calculated and state how it was determined):
	(4)	Proposed maximum aggregate value of transaction:
	(5)	Total fee paid:

☐	Fee paid previously with preliminary materials.

☐	Check box if any part of the fee is offset as provided by Exchange Act Rule 0-11(a)(2) and identify the filing for which the offsetting fee was paid previously. Identify the previous filing by registration statement number, or the Form or Schedule and the date of its filing.

	(1)	Amount Previously Paid:
	(2)	Form, Schedule or Registration Statement No.:
	(3)	Filing Party:
	(4)	Date Filed:


		Here’s how to order a copy of the proxy materials and select delivery preferences: Current and future delivery requests can be submitted using the options below. If you request an email copy, you will receive an email with a link to the current meeting materials. PLEASE NOTE: You must use the number in the shaded bar on the reverse side when requesting a copy of the proxy materials.

		–		Internet - Go to www.investorvote.com/teva.

		–		Phone - Call us free of charge at 1-866-641-4276.

		–		Email - Send an email to investorvote@computershare.com with “Proxy Materials Teva Pharmaceutical Industries Limited” in the subject line. Include your full name and address, plus the number located in the shaded bar on the reverse side, and state that you want a paper copy of the meeting materials.

				To facilitate timely delivery, requests for a paper copy of proxy materials must be received by May 27, 2022



1.	Election of Directors
	Nominees:
1A.	Amir Elstein	For

1B.	Roberto A. Mignone	For

1C.	Dr. Perry D. Nisen	For

1D.	Dr. Tal Zaks	For

2.	To approve, on a non-binding advisory basis, the compensation for Teva’s named executive officers.	For

3.	To approve Teva’s Compensation Policy with respect to the Terms of Office and Employment of Teva’s Executive Officers and Directors.	For

3A.	Regarding proposal 3, please indicate when you vote whether or not you are a controlling shareholder of Teva and whether or not you have a personal benefit or other interest in this proposal*

4.	To approve amendments to Teva’s Articles of Association.	For

5.	To appoint Kesselman & Kesselman, a member of PricewaterhouseCoopers International Ltd., as Teva’s independent registered public accounting firm until Teva’s 2023 annual meeting of shareholders.	For

NOTE: In addition, shareholders will consider Teva’s annual consolidated financial statements for the year ended December 31, 2021. *IMPORTANT NOTE: if you do not complete this section, or if you indicate that you are a controlling shareholder or that you have a personal benefit or other interest in the proposal, your vote on proposal 3 will not be counted for purposes of the Disinterested Majority. See the Proxy Statement for more information, including the definitions of these terms under the Israeli Companies Law. Teva is not currently aware of any controlling shareholder, as defined under the Israeli Companies Law, and believes that the vast majority of its shareholders should not have a personal benefit or other interest in proposal 3.


		Obtaining a copy of the Proxy Materials – If you want to receive a copy of the proxy materials, you must request one. There is no charge to you for requesting a copy. Please make your request as instructed on the reverse side on or before May 27, 2022 to facilitate timely delivery. Unless requested, you will not otherwise receive a paper or email copy.




				Your Vote Counts!
				TEVA PHARMACEUTICAL INDUSTRIES LIMITED 2022 Annual Meeting Vote by June 20, 2022 11:59 PM ET









D82098-P74050


Voting Items				Board Recommends